Tag: Bendamustine

As a potent chemotherapy agent, bendamustine administration is a critical procedure that requires adherence to specific protocols to ensure patient safety and therapeutic efficacy. Administered as an intravenous infusion, the process involves precise preparation, careful monitoring, and strict handling due to its hazardous nature. This guide provides a detailed overview of the steps involved for healthcare professionals and offers essential information for patients receiving this treatment.

According to its FDA approval, Bendeka is indicated for the treatment of two types of blood cancer: chronic lymphocytic leukemia (CLL) and a specific type of non-Hodgkin lymphoma (NHL). As an intravenous chemotherapy agent, Bendeka's purpose is to interfere with and kill cancer cells.

First approved in the U.S. in 2008, bendamustine (brand names including Treanda and Bendeka) is a potent chemotherapy agent used to treat chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin's lymphoma (NHL). As an alkylating agent, it damages the DNA of cancer cells, which ultimately leads to their destruction.